These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24722207)

  • 1. Overexpression of LARGE suppresses muscle regeneration via down-regulation of insulin-like growth factor 1 and aggravates muscular dystrophy in mice.
    Saito F; Kanagawa M; Ikeda M; Hagiwara H; Masaki T; Ohkuma H; Katanosaka Y; Shimizu T; Sonoo M; Toda T; Matsumura K
    Hum Mol Genet; 2014 Sep; 23(17):4543-58. PubMed ID: 24722207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
    Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
    Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
    Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
    Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A.
    Yamauchi J; Kumar A; Duarte L; Mehuron T; Girgenrath M
    Hum Mol Genet; 2013 Nov; 22(21):4306-17. PubMed ID: 23773998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
    Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
    Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant neuromuscular junctions and delayed terminal muscle fiber maturation in alpha-dystroglycanopathies.
    Taniguchi M; Kurahashi H; Noguchi S; Fukudome T; Okinaga T; Tsukahara T; Tajima Y; Ozono K; Nishino I; Nonaka I; Toda T
    Hum Mol Genet; 2006 Apr; 15(8):1279-89. PubMed ID: 16531417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice.
    Bentzinger CF; Barzaghi P; Lin S; Ruegg MA
    FASEB J; 2005 Jun; 19(8):934-42. PubMed ID: 15923403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
    Toda T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dystroglycanopathy muscles lacking functional glycosylation of alpha-dystroglycan retain regeneration capacity.
    Awano H; Blaeser A; Wu B; Lu P; Keramaris-Vrantsis E; Lu Q
    Neuromuscul Disord; 2015 Jun; 25(6):474-84. PubMed ID: 25937147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fukutin expression in mouse non-muscle somatic organs: its relationship to the hypoglycosylation of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy.
    Saito Y; Yamamoto T; Ohtsuka-Tsurumi E; Oka A; Mizuguchi M; Itoh M; Voit T; Kato Y; Kobayashi M; Saito K; Osawa M
    Brain Dev; 2004 Oct; 26(7):469-79. PubMed ID: 15351084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant glycosylation of alpha-dystroglycan causes defective binding of laminin in the muscle of chicken muscular dystrophy.
    Saito F; Blank M; Schröder J; Manya H; Shimizu T; Campbell KP; Endo T; Mizutani M; Kröger S; Matsumura K
    FEBS Lett; 2005 Apr; 579(11):2359-63. PubMed ID: 15848172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal Skeletal Muscle Regeneration plus Mild Alterations in Mature Fiber Type Specification in Fktn-Deficient Dystroglycanopathy Muscular Dystrophy Mice.
    Foltz SJ; Modi JN; Melick GA; Abousaud MI; Luan J; Fortunato MJ; Beedle AM
    PLoS One; 2016; 11(1):e0147049. PubMed ID: 26751696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
    Xiong H; Kobayashi K; Tachikawa M; Manya H; Takeda S; Chiyonobu T; Fujikake N; Wang F; Nishimoto A; Morris GE; Nagai Y; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2006 Dec; 350(4):935-41. PubMed ID: 17034757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages.
    Meinen S; Barzaghi P; Lin S; Lochmüller H; Ruegg MA
    J Cell Biol; 2007 Mar; 176(7):979-93. PubMed ID: 17389231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.
    Aoki Y; Nagata T; Yokota T; Nakamura A; Wood MJ; Partridge T; Takeda S
    Hum Mol Genet; 2013 Dec; 22(24):4914-28. PubMed ID: 23882132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding.
    Yoshida-Moriguchi T; Yu L; Stalnaker SH; Davis S; Kunz S; Madson M; Oldstone MB; Schachter H; Wells L; Campbell KP
    Science; 2010 Jan; 327(5961):88-92. PubMed ID: 20044576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.
    Xu R; Chandrasekharan K; Yoon JH; Camboni M; Martin PT
    Am J Pathol; 2007 Jul; 171(1):181-99. PubMed ID: 17591965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of dysferlin deficiency to skeletal muscle pathology in asymptomatic and severe dystroglycanopathy models: generation of a new model for Fukuyama congenital muscular dystrophy.
    Kanagawa M; Lu Z; Ito C; Matsuda C; Miyake K; Toda T
    PLoS One; 2014; 9(9):e106721. PubMed ID: 25198651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congenital muscular dystrophy with glycosylation defects of alpha-dystroglycan in Japan.
    Matsumoto H; Hayashi YK; Kim DS; Ogawa M; Murakami T; Noguchi S; Nonaka I; Nakazawa T; Matsuo T; Futagami S; Campbell KP; Nishino I
    Neuromuscul Disord; 2005 May; 15(5):342-8. PubMed ID: 15833426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.